20.55
+0.02(+0.10%)
Currency In USD
| Previous Close | 20.53 |
| Open | 20.43 |
| Day High | 20.58 |
| Day Low | 20.26 |
| 52-Week High | 26.58 |
| 52-Week Low | 19.05 |
| Volume | 940,996 |
| Average Volume | 1.51M |
| Market Cap | 2.52B |
| PE | 12.45 |
| EPS | 1.65 |
| Moving Average 50 Days | 20.22 |
| Moving Average 200 Days | 22.1 |
| Change | 0.02 |
If you invested $1000 in Catalyst Pharmaceuticals, Inc. (CPRX) 10 years ago, it would be worth $6,026.39 as of October 19, 2025 at a share price of $20.55. Whereas If you bought $1000 worth of Catalyst Pharmaceuticals, Inc. (CPRX) shares 5 years ago, it would be worth $6,323.08 as of October 19, 2025 at a share price of $20.55.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
GlobeNewswire Inc.
Oct 09, 2025 12:03 PM GMT
CORAL GABLES, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for people living
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program
GlobeNewswire Inc.
Oct 01, 2025 12:03 PM GMT
CORAL GABLES, Fla., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for
UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
GlobeNewswire Inc.
Aug 26, 2025 11:12 PM GMT
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035CORAL GABLES, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-s